主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ALGS
#3397
Aligos Therapeutics, Inc. Common Stock
7.030
0
+1.30%
版块:
基础:
利润货币:
日范围
年范围
日变化
+1.30%
每月变动
-19.10%
6个月变化
-28.19%
年变化
-28.19%
前一天收盘价
6.940
0
Open
7.030
0
Bid
Ask
Low
7.030
0
High
7.030
0
交易量
2
市场
股票
医疗保健
ALGS
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.53 M
1.58 M
1.59 M
2.9 M
6.11 M
—
Valuation ratios
Enterprise value
—
—
—
—
—
—
Price to earnings ratio
—
—
—
—
-1.9
-4.32
Price to sales ratio
—
—
—
—
46.99
87.35
Price to cash flow ratio
—
—
—
—
3.09
5.58
Price to book ratio
—
—
—
—
8.61
9.32
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.41
-0.55
-0.65
-0.58
-1.87
-1.5
Return on equity %
-0.49
-0.69
-0.92
-0.95
-4.53
-3.38
Return on invested capital %
-1 521.51
-1 526.49
-1 163.95
-1 725.24
-2 679.38
-3 114.08
Gross margin %
—
—
—
100
100
400
Operating margin %
—
—
—
-840.02
-1 678.67
-7 847.54
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
-835.75
-2 470.55
-11.14 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
8.26
5.25
4.03
5.9
2.86
21.43
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0.07
0.05
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
4 682.15
17.65 K
69.13 K
-30.73
-12.89
-9.49
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
-15.35 K
-31.4 K
-109.54 K
52.79
9.08
48.19
Net current asset value per share
-15.76 K
-31.19 K
-116.28 K
54.89
9.92
50.61
Tangible book value per share
-13.87 K
-28.19 K
-90.47 K
35.82
-4.62
26.97
Working capital per share
-13.85 K
-25.25 K
-87.44 K
45.59
6.45
40.55
Book value per share
-13.87 K
-28.19 K
-90.47 K
35.82
-4.62
26.97
新闻
H.C. Wainwright维持Aligos Therapeutics股票买入评级,看好pevifoscorvir研发进展
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
Aligos Therapeutics股价因乙肝二期研究进展而上涨
Aligos Therapeutics stock rises on Phase 2 HBV study progress
Aligos公布乙肝药物二期研究进展
Aligos reports progress on Phase 2 hepatitis B drug study
Aligos Therapeutics任命James Hassard为首席商务官
Aligos therapeutics appoints James Hassard as chief commercial officer
UBS以肝脏疾病管线为由给Aligos Therapeutics股票首次评级为"买入"
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
Aligos报告THR-β激动剂协同减重效果
Aligos reports synergistic weight loss effect with THR-β agonist